149355-52-2

Usage

Uses

Used in Organic Synthesis:
7-Cyano-1,2,3,4-tetrahydroisoquinoline is used as a building block in organic synthesis for the creation of various bioactive molecules. Its unique structure and functional group contribute to the synthesis of a wide range of compounds with potential applications in different fields.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 7-cyano-1,2,3,4-tetrahydroisoquinoline is utilized as a key intermediate in the development of new pharmaceuticals. Its ability to act as a dopamine receptor antagonist makes it a promising candidate for the treatment of neurological disorders and other conditions related to dopamine dysregulation.
Used in Drug Discovery:
7-Cyano-1,2,3,4-tetrahydroisoquinoline is employed as a valuable compound in drug discovery, where its structure and properties are leveraged to identify and develop novel therapeutic agents. Its potential as a ligand in coordination chemistry further expands its applications in the design and synthesis of new drugs.
Used in Chemical Biology:
In chemical biology, 7-cyano-1,2,3,4-tetrahydroisoquinoline serves as a versatile compound for studying biological processes and interactions. Its unique structure allows for the exploration of its potential roles in various biological systems, contributing to a deeper understanding of its mechanisms of action and potential applications in therapeutic interventions.

InChI:InChI=1/C10H10N2/c11-6-8-1-2-9-3-4-12-7-10(9)5-8/h1-2,5,12H,3-4,7H2

Upstream product

• 72299-68-4 1,2,3,4-Tetrahydro-isoquinolin-7-ylamine 
• 149354-03-0 7-cyano-3,4-dihydroisoquinolin-2(1H)-carboxylic acid t-butyl ester 
• 258515-65-0 7-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylic acid tert-butyl ester 
• 17680-55-6 7-bromo-1,2,3,4-tetrahydroisoquinoline 
• 99365-69-2 7-nitro-1,2,3,4-tetrahydroisoquinoline hydrochloride 
• 151-50-8 potassium cyanide 

Downstream Products

• 200137-82-2 2-Trityl-1,2,3,4-tetrahydro-isoquinoline-7-carbonitrile 
• 220247-50-7 methyl 1,2,3,4-tetrahydroisoquinoline-7-carboxylate 
• 215790-43-5 trans-2-(2-(1-4-(N-tert-butyloxycarbonyl)amino)cyclohexyl)ethyl-7-cyano-1,2,3,4-tetrahydroisoquinoline 
• 215802-15-6 SB 269652 
• 1030019-28-3 C₁₈H₁₆N₂O₂ 
• 903556-96-7 tert-butyl (2-benzyloxycarbonyl-1,2,3,4-tetrahydroisoquinolin-7-yl)methylcarbamate 
• 685565-52-0 N-[4-(3-piperidin-1-ylpropoxy)benzoyl]-7-cyano-1,2,3,4-tetrahydroisoquinoline 
• 1394241-70-3 C₁₇H₁₄N₂O₄S 
• 1394241-64-5 C₁₇H₁₅N₅O₄S 
• 200137-84-4 N-(2-Trityl-1,2,3,4-tetrahydro-isoquinolin-7-ylmethyl)-methanesulfonamide 
• 200137-83-3 C-(2-Trityl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-methylamine 

Relevant academic research and scientific papers

NOVEL TETRAHYDROISOQUINOLINES AND TERAHYDRONAPHTHYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The present invention provides novel compounds having the general formula (I): wherein R1, R 2, R 3, U, V, W, X and Y are as described herein, compositions including the compounds and methods of using the compounds.

Substituted Spiroamide Compounds

Substituted spiroamide compounds corresponding to formula (I): wherein A, B, Q1, Q2, Q3, Q4, R1, R8, R9a, R9b, R12, R13, R200 and R210 have defined meanings, processes for their preparation, pharmaceutical compositions containing such compounds, and the use of such compounds for treating or inhibiting pain or other conditions mediated at least in part by the bradykinin 1 receptor (B1R).

Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK and F 29661) toward inhibition of phenylethanolamine N-methyltransferase vs the α2-adrenoceptor

7-(Aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK and F 29661, 1) is a potent inhibitor of the enzyme phenylethanolamine N-methyltransferase (PNMT, EC 2.1.1.28). In contrast to other inhibitors of PNMT, it is also highly selective toward PNMT in compar

2-pyrrolidinones, pharmaceutical compositions containing these compounds and processes for preparing them

The invention relates to cyclic imino derivatives of general formula wherein A, B, E, X2 to X5 and Y are defined as in claim 1, the stereoisomers, tautomers, mixtures and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable pharmacological properties, preferably aggregation-inhibiting effects, pharmaceutical compositions which contain these compounds and processes for preparing them.